<DOC>
	<DOCNO>NCT01423149</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy 3 dose group ( 27 , 36 45 mg/m2 ) Combretastatin A-4 Phosphate treatment subfoveal choroidal neovascularization subject pathologic myopia .</brief_summary>
	<brief_title>Safety Efficacy Study Combretastatin A4 Phosphate Treat Patients With Choroidal Neovascularization Secondary Pathologic Myopia</brief_title>
	<detailed_description />
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Myopia , Degenerative</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>Provide write informed consent Be able willing follow instruction Age 18 50 year old ( inclusive ) Have area CNV within 50 um geometric center foveal avascular zone Have greatest linear dimension lesion 5,400 um less , &gt; /=50.0 % lesion compose CNV ( feature obscure boundary CNV blood , serous pigment epithelial detachment block fluorescence must occupy &lt; 50.0 % ) confirm Doheny Image Reading Center ( DIRC ) Have best correct distance visual acuity ( ETDRS ) 20/20 20/200 ( LogMAR +0.0 1.0 ) , inclusive qualifying eye ( ) Have pathologic myopia present 6.0 diopter correction require OR axial length &gt; /= 26.5 mm Be able willing avoid medication investigator feel may interfere study If female childbearing potential , agree submit sample pregnancy test negative pregnancy test within 1 day prior treatment . Females consider childbearing potential unless surgically sterile postmenopausal 12 month . Females childbearing potential must agree approved form contraception duration study . Have contraindication , allergy sensitivity use study medication Have clinical sign symptom , opinion investigator , may interfere study Features condition pathologic myopia associate CNV , agerelated macular degeneration Have tear retinal pigmented epithelium Have undergo ocular therapy/surgery major surgery last 3 month surgery plan study period Have significant illness condition , ocular systemic could , opinion investigator , expect interfere study Have angina ( stable severe , even control medication ) , 6 month S/P myocardial infarction , congestive heart failure , history presence clinically significant supraventricular ventricular arrhythmia syncope episode Have ECG QTc &gt; 450 msdec clinically significant abnormality leave bundle branch block , leave ventricular hypertrophy , etc . Have uncontrolled QTc prolongation Take drug know prolong QTc interval however subject remain eligible nonQTc substitute administer Have uncontrolled hypertension ( define blood pressure consistently great 150/100 mm Hg irrespective medication ) Uncontrolled hypokalemia and/or hypomagnesemia Have symptomatic peripheral vascular disease cerebrovascular disease Have psychiatric disorder condition render subject incapable comply requirement protocol Be receive concurrent hormonal therapy exception Gonadotropinreleasing hormone agonist subject hormone refractory prostate cancer , hormone replacement therapy , oral contraceptive , megestrol acetate use anorexia/cachexia Be receive anticoagulation warfarin , heparin low molecular weight heparin low dose ( 1 mg ) warfarin maintenance Hickman line patency Be woman currently pregnant , nursing , plan pregnancy ; woman positive pregnancy test Have participate investigational drug device trial within 30 day enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>subfoveal choroidal neovascularization</keyword>
	<keyword>pathologic myopia</keyword>
</DOC>